TianjinJune 18, 2026 /PRNewswire/ — On June 14, 2026, the first and second phases of the intelligent manufacturing base of Qingsong (Tianjin) Pharmaceutical Co., Ltd. were officially completed and put into operation.
The project has a total investment of 1.1 billion yuan.
Viewing it merely as the inauguration of a new factory would clearly underestimate its value.
From the localization of high-end formulations to the construction of a digital factory; from green and low-carbon operations to the adoption of international standards, this factory reflects a new direction for the upgrading of China’s pharmaceutical industry.
For the industry, it sends four noteworthy signals.
Signal 1: Localization of high-end formulations is accelerating
The base focuses on the production of dual-chamber bag products for carbapenem antibiotics.
As an important drug for treating severe infections, carbapenem antibiotics are highly sensitive to oxygen and moisture, and have long faced high technical barriers and production difficulties.
Qingsong Pharmaceutical independently developed the dual-chamber bag packaging process, overcoming key technologies such as intermediate weak welding, achieving stable control of the product throughout production, transportation, and clinical use.
Compared with traditional vial dispensing, dual-chamber bag products eliminate steps like opening bottles, drawing liquids, and transferring. They mix upon squeezing, offering faster, safer, and more clinically aligned operations.
This is not just a breakthrough for a single product, but an enhancement of the localization capability for high-end anti-infective formulations.
Signal 2: Digitization is moving toward full-factory implementation
Digitization has become a consensus in the pharmaceutical industry, but few projects achieve truly coordinated system-wide operation.
Qingsong Pharmaceutical’s Tianjin base was designed as a digital factory from the planning stage.
The project was implemented by Pu Gong Ying’s Yaoda software in collaboration with partners such as Rockwell Automation, building a digital system covering the entire production lifecycle. Core systems including DMS, TMS, QMS, LIMS, MES, BMS, and EMS were developed, validated, and operated simultaneously.
From personnel training to quality management, and from production execution to energy management, full-process digital traceability is achieved.
Digitization is no longer just a showcase; it is becoming the infrastructure of modern pharmaceutical factories.
Signal 3: Green factories are becoming the standard
In the past, factory construction focused on production capacity.
Today, it focuses more on energy consumption and sustainable development.
Qingsong Pharmaceutical’s Tianjin base incorporated ESG concepts from the design stage.
The project uses imported Italian P3 air duct systems and partners with companies like Yishi Technology to create a safe, energy-efficient, and intelligent integrated clean environment solution.
Lower energy consumption, higher stability, and better operational efficiency are key features of the project.
As international markets increasingly demand green manufacturing, green factories are no longer a bonus but a crucial component of competitiveness.
Signal 4: Building for the future with international standards
Notably, the project was designed for the international market from the outset.
The base fully references FDA and EU GMP standards, systematically designing factory layout, clean systems, automation control, and quality management.
In the past, factories were built to meet production needs;
Today, factories are built to gain access to global markets.
This shift is becoming a new choice for more Chinese pharmaceutical companies.
From one factory, we see an industry.
The launch of Qingsong Pharmaceutical’s Tianjin intelligent manufacturing base is a key milestone for the company and a microcosm of the upgrading of China’s pharmaceutical industry.
High-end formulations, digital factories, green manufacturing, international standards.
Behind these keywords lies the transition of China’s pharmaceutical industry from scale expansion to capability enhancement.
Future competition is not just about products, but about manufacturing capabilities.
And Qingsong Pharmaceutical’s 1.1 billion yuan intelligent manufacturing base is providing a new benchmark for the industry.
